迈威生物：注射用7MW4911获得《药物临床试验批准通知书》

Group 1 - The core point of the article is that Maiwei Biotech has received approval from the National Medical Products Administration for the clinical trial of its injectable drug 7MW4911 [1] - Maiwei Biotech's revenue composition for the year 2024 is projected to be 99.92% from the pharmaceutical manufacturing industry and 0.08% from other businesses [1] - As of the report, Maiwei Biotech has a market capitalization of 17.7 billion yuan [1]